Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist.
about
The year in review: surgical revascularization of coronary artery disease--2011.Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease.The optimal pharmacological formula for percutaneous coronary intervention.Ticagrelor: a review of its use in the management of acute coronary syndromes.Antiplatelet drug therapy: role of pharmacodynamic and genetic testing.Managing adverse effects and drug-drug interactions of antiplatelet agents.Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist.Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease.Atopaxar: a review of its mechanism of action and role in patients with coronary artery disease.Facilitated/pharmaco-invasive approaches in STEMI.Platelet function profiles in patients with diabetes mellitus.Dual antiplatelet therapy in patients with diabetes mellitus: special considerations.Antiplatelet therapy: new pharmacological agents and changing paradigms.Updates in antiplatelet agents used in cardiovascular diseases.Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention.Role of Genetic Testing in Patients undergoing Percutaneous Coronary Intervention.Ticagrelor: The first approved reversible oral antiplatelet agent.Elinogrel: pharmacological principles, preclinical and early phase clinical testing.Critical Role of P2Y12 Receptor in Regulation of Th17 Differentiation and Experimental Autoimmune Encephalomyelitis Pathogenesis.
P2860
Q34279179-A9413C2E-07B5-4260-9925-135E0FBE37ECQ37797795-FFD36531-F9BE-48ED-BAE8-97BDD71E0B75Q37830053-281541DE-9963-436B-9E7C-0F343B23B8D8Q37875063-101E0D6B-44D3-4286-9245-8EB72F775AD2Q37882712-697A8685-74AD-4C63-82EB-24C6CA7134C4Q37930967-B241A83F-27DF-4F32-BBDB-FBA540752B69Q38009746-945E4604-0CBA-42CC-8B70-708A87222553Q38027576-B615828B-CD49-4675-AE58-5605830B7CC8Q38032614-19E517E1-F78C-48C7-A319-0EEFADD950F8Q38037668-4F1DAF9D-5A6A-4AB4-BDDE-398F80B13637Q38081078-79BB0E0F-0941-4031-8524-8754693FCA23Q38087381-3BD53658-62BB-42DE-8AB4-D4DED3D6364EQ38117743-15757D68-5BCC-4412-B4E8-13F666C797E6Q38161394-691EDBD1-4402-42D3-AE64-E0126AF57077Q38378830-A28EAD2B-9FCF-4B2F-9E26-3904AF547A02Q38401281-E30490BB-6DDC-49A8-8279-50E0A8A4F57AQ42149188-7931D91C-AE41-4B1E-9BA3-711F447F7E38Q42978644-B894A8A5-D833-47DF-B27A-00E789430E77Q50995948-515CAD6D-2609-4FE0-BEE6-9B61674EC7BA
P2860
Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mechanism of action and clinic ...... ADP P2Y12 receptor antagonist.
@en
Mechanism of action and clinic ...... ADP P2Y12 receptor antagonist.
@nl
type
label
Mechanism of action and clinic ...... ADP P2Y12 receptor antagonist.
@en
Mechanism of action and clinic ...... ADP P2Y12 receptor antagonist.
@nl
prefLabel
Mechanism of action and clinic ...... ADP P2Y12 receptor antagonist.
@en
Mechanism of action and clinic ...... ADP P2Y12 receptor antagonist.
@nl
P2860
P356
P1476
Mechanism of action and clinic ...... ADP P2Y12 receptor antagonist.
@en
P2093
Dominick J Angiolillo
Kodlipet Dharmashankar
P2860
P304
P356
10.1586/ERC.09.172
P577
2010-02-01T00:00:00Z